Jeffrey C. Thacker
Jeff is a partner in our San Diego office.
Jeff practices corporate and securities law, representing both public and private companies and venture capital funds. He has deep experience advising life science, AI and technology companies in a variety of transactions, including IPOs and other public offerings, venture financings and mergers and acquisitions.
He has worked with Foresite Labs to incubate and fund more than 20 AI and life science companies, including Prometheus Industries, Xaira, Radian Bio, Catharos, Candid Therapeutics, Element Biosciences, Kymathera and Katharos.
Jeff’s representation of public companies includes Anterix, Contineum Therapeutics, Natera and Palisade Bio. He also represented CareFusion until its sale to BD for $12.2 billion and Life Technologies until its sale to Thermo Fisher for $13.6 billion.
Webinar
What to Know About Crossover Rounds as a Late-Stage Private Company
Gunderson Dettmer partners Ryan Gunderson and Jeff Thacker hosted a discussion on the benefits and considerations of raising capital from crossover funds as part of an IPO Summit series of workshops. The panel provided an overview of the benefits of raising capital from crossover funds from both the company and the investor perspective, as well as discussed practical considerations when choosing investors for any crossover.
Related News & Insights
Related News & Insights
Client News
